Mepolizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Mepolizumab and local guidelines before prescribing.
Anti-IL-5 monoclonal antibody
Mechanism
Anti-IL-5 monoclonal antibody.
Uses
Severe eosinophilic asthma, EGPA, hypereosinophilic syndrome.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Headache, injection-site reaction, back pain, herpes zoster.
Interactions
Few.
Contraindications and cautions
Active parasitic infection
Monitoring
Eosinophils, asthma control
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Treat helminth infections first; do not stop inhaled steroids abruptly.
More from the textbook: uses, cautions and other points
- Treatment: High-dose corticosteroids; imatinib for FIP1L1-PDGFRA -positive disease; anti-IL-5 therapy (mepolizumab) in selected cases; anticoagulation for thrombus; surgery for late fibrosis or valve disease.
Cardiology: Cardiomyopathies - Mepolizumab , reslizumab | IL-5 (eosinophil growth and survival) | Severe eosinophilic asthma; mepolizumab also for EGPA and some nasal polyps
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab / mepolizumab / benralizumab / dupilumab / tezepelumab | Biologics for severe asthma (specialist).
Respiratory: Anatomy, Physiology and Pharmacology - Severe eosinophilic asthma on maintenance prednisolone | Refer for biologic (e.g. mepolizumab, benralizumab)
Respiratory: Anatomy, Physiology and Pharmacology - Mepolizumab , reslizumab (anti-IL-5) and benralizumab (anti-IL-5 receptor): Severe eosinophilic asthma.
Respiratory: Airways Disease - Specialist immunosuppression; mepolizumab.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - EGPA - steroids; mepolizumab (anti-IL-5) for relapsing or refractory disease.
Renal: Glomerular Disease
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Respiratory: Anatomy, Physiology and Pharmacology (3 mentions)
- Respiratory: Airways Disease (3 mentions)
- Renal: Glomerular Disease (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: Vasculitis, GCA and PMR (2 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated cardiology chapter (1 mention)
- Integrated respiratory chapter (3 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)